Skip to content

COVID-19 and medical cannabis patients: What you need to know

March 27, 2020 / Arfinn Med MD /

COVID-19 and medical cannabis patients: What you need to know

In the midst of the COVID-19 maelstrom, the recent shuttering of nonessential stores has created concern around access to cannabis, particularly for medicinal cannabis consumers. Those who depend on cannabis for therapeutic purposes will be relieved to learn that across the US, medical cannabis dispensaries have been deemed essential services, comparable to pharmacies.

As of March 26, 2020, the Marijuana Policy Project (MPP) reported that they were not aware of any jurisdictions where medical cannabis dispensaries have been ordered to close temporarily. In counties such as Denver, care has been taken to specify that while recreational dispensaries will close, medical dispensaries will remain exempt. Most state government agencies seem to be acutely aware of medicinal patients’ needs.

But even with the reassurance of ongoing access to medical dispensaries, a host of other questions have arisen: How can immuno-compromised patients safely access cannabis supplies without endangering their health? Is hoarding or stockpiling supplies prudent in light of soaring cannabis sales across the US?

Read Full Article Here

Stories you may be interested in

Arfinn Med Patient Site

We get a lot of interest from patients asking about efficacy data for medical marijuana on a number of conditions. Though we are primarily an electronic medical record (EMR) company focussing on the cannabis industry and other complimentary or alternative therapies, our primary focus is better quality care for patients. So with that being said,…
Read More →

LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY

There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed. Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed…
Read More →

Updated Arfinn Med Scheduler

As your practice begins to grow, it’s important that your booking system is able to keep up.  That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform.  This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More →

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More →

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More →

Finally, Georgia can grow medical marijuana. Here’s what you need to know.

Four years ago, Governor Nathan Deal signed into law Haleigh’s Hope Act, which made low-THC cannabis oil legal to use by those with certain medical conditions. However, as it was still against the law to buy or grow marijuana in the state, it was virtually impossible to obtain the oil in Georgia. Patients were forced…
Read More →

Leave a Comment

You must be logged in to post a comment.